Publication: Effectiveness of deferiprone in transfusionindependent beta-thalassemia/HbE patients
Issued Date
2011-03-01
Resource Type
ISSN
16078454
10245332
10245332
Other identifier(s)
2-s2.0-79952658675
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Hematology. Vol.16, No.2 (2011), 113-122
Suggested Citation
Krittapoom Akrawinthawong, Nithima Chaowalit, Thanasaporn Chatuparisuth, Noppadol Siritanaratkul Effectiveness of deferiprone in transfusionindependent beta-thalassemia/HbE patients. Hematology. Vol.16, No.2 (2011), 113-122. doi:10.1179/102453311X12940641877768 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/12592
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Effectiveness of deferiprone in transfusionindependent beta-thalassemia/HbE patients
Other Contributor(s)
Abstract
Beta-thalassemia/HbE (beta-thal/HbE) is a thalassemia intermedia (TI) which encompasses a broad spectrum of severity. Here, we used deferiprone (DFP) as an iron chelating agent in TI patients receiving intermittent blood transfusion who are asymptomatic for cardiovascular disease in order to evaluate the effectiveness in iron overload and reduce the possibility of cardiovascular complications. Thirty transfusionin-dependent beta-thal/HbE patients with iron overload were treated with DFP for 1 year. Hematological, biochemical, oxidative stress and echocardiographic parameters were determined. Serum ferritin, nontransferrin-bound iron, and malondialdehyde decreased significantly (P < 0.05) after 1-year treatment with DFP. For echocardiographic results, mean pulmonary arterial pressure and pulmonary vascular resistance were diminished significantly (P < 0.05). All those parameters were still improved after subgroup analysis was done for the high ferritin group ( > 2500 ng/ml). DFP therapy alone improved iron overload and oxidative stress and compliance was good. We propose that prevention of pulmonary hypertension is also possible for TI undergoing intermittent blood transfusion. © W. S. Maney & Son Ltd 2011.